More Post from the Author
- Visionary Holdings Inc. Receives Nasdaq Notification Regarding Delayed Form 20-F Filing
- Rand McNally Introduces Truck-Safe Connected Navigation Powered by Rand Road IQ on Platform Science
- CGTN AMERICA CCTV UN: ,
- Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics
- Agricultural Intelligence Leader Ceres AI Secures Growth Financing Package from Decathlon Capital Partners
Nanomi Receives CMO Award for Life Science Leadership in Drug Delivery
MUMBAI, India and Oldenzaal, Netherlands, March 21, 2025 /PRNewswire/ -- Nanomi B.V., a Dutch subsidiary of the global pharma major Lupin Limited, today announced that it has won the prestigious CMO Award for Life Science Leadership in Drug Delivery, during the Drug, Chemical and Associated Technologies Association (DCAT) week at New York.
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare.
Dr. Shahin Fesharaki, Global Chief Scientific Officer, Lupin, said, "This recognition underscores our dedication to advancing science and highlights Nanomi's pioneering efforts in drug delivery. We remain committed to innovation that enables the delivery of high-quality medicines that significantly improve patient outcomes."
Established in 2011, the CMO Leadership Awards are presented by Outsourced Pharmaand Life Science Connectwith research by Orientation Marketingand recognize top outsourcing partners, based on the feedback from sponsor companies who outsource manufacturing. This year is the first year that the CMO Leadership Award is juried.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnologyproducts, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visitwww.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin.
To know more about Nanomi, visit www.nanomi.comor follow on LinkedIn https://www.linkedin.com/company/nanomi.
Logo:https://mma.prnewswire.com/media/2461104/4811288/Lupin_Logo.jpg
Logo -https://mma.prnewswire.com/media/2647166/Nanomi_Logo.jpg

More Post from the Author
- Visionary Holdings Inc. Receives Nasdaq Notification Regarding Delayed Form 20-F Filing
- Rand McNally Introduces Truck-Safe Connected Navigation Powered by Rand Road IQ on Platform Science
- CGTN AMERICA CCTV UN: ,
- Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics
- Agricultural Intelligence Leader Ceres AI Secures Growth Financing Package from Decathlon Capital Partners

